MedPath

Intellia Therapeutics Price Target Lowered by Wells Fargo

Wells Fargo has reduced the price target for Intellia Therapeutics from $80 to $70, while maintaining an Overweight rating on the shares, citing promising Phase 1 ATTR-CM data for nex-z.

Wells Fargo has adjusted its price target for Intellia Therapeutics (NTLA), lowering it to $70 from the previous $80, yet continues to recommend an Overweight rating on the shares. This adjustment comes in light of the Phase 1 ATTR-CM data for nex-z, which, according to the firm, compares favorably against historical data from silencers and stabilizers. Notably, this comparison holds despite a greater proportion of patients in the study having more severe disease. Wells Fargo believes that these findings are indicative of potential success in the upcoming Phase 3 trials.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Wells Fargo Lowers Intellia Therapeutics Price Target to $60

Wells Fargo has reduced its price target for Intellia Therapeutics from $70 to $60, maintaining an Overweight rating. The adjustment follows the discontinuation of the Alpha-1 Antitrypsin Deficiency program, with the firm highlighting ATTR amyloidosis with cardiomyopathy as the primary value driver.

Intellia Therapeutics Announces Strategic Reorganization and 2025 Milestones

Intellia Therapeutics, Inc. (NTLA) has announced a strategic reorganization focusing on its late-stage programs, NTLA-2002 and nex-z, targeting hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively. The company also disclosed a 27% workforce reduction and an $8 million restructuring charge. Additionally, Intellia's price target was adjusted by BMO Capital and Wells Fargo, reflecting changes in its strategic direction and clinical trial progress.

Vir Biotechnology's T-Cell Engagers Show Promise in Early Cancer Trials, Morgan Stanley Upgrades Stock

Vir Biotechnology's VIR-5818 and VIR-5500 demonstrate encouraging safety and early clinical response in heavily pretreated cancer patients.
Phase 1 data reveals dose-dependent tumor shrinkage in HER2-positive tumors with VIR-5818 and a 58% PSA50 response rate in prostate cancer with VIR-5500.

Vertex Pharmaceuticals Faces Mixed Outlook for Suzetrigine After Phase 2 Data

Vertex Pharmaceuticals' Suzetrigine showed less promising Phase 2 results for lumbosacral radiculopathy, reducing the probability of success from 50% to 15%.
Despite the LSR setback, optimism remains high for Suzetrigine in acute pain treatment, with anticipated FDA approval based on positive Phase 3 trial outcomes.

Exelixis Downgraded to Market Perform Despite Price Target Increase to $40

BMO Capital Markets downgraded Exelixis Inc. from Outperform to Market Perform, raising the price target to $40 due to a cautious outlook on the company's growth prospects, despite a 56% stock gain over six months. The focus is on zanzalintinib's trial for colorectal cancer, with success probability increased to 50%, amidst uncertainties from cabometyx's mixed track record.

Tyra Biosciences Stock Target Adjusted Following Clinical Data Review

H.C. Wainwright has adjusted Tyra Biosciences' stock price target to $30 from $32 while maintaining a Buy rating, following a review of clinical data for its lead compound, TYRA-300. The drug showed promising results in treating non-muscle-invasive bladder cancer and metastatic urothelial carcinoma, with a favorable safety profile.

Acelyrin's Izo Fails Phase 2b/3 Trial in Uveitis; Wells Fargo Adjusts Price Target

Acelyrin's Phase 2b/3 trial of izokibep (izo) in uveitis has failed, leading to the removal of its contribution from Wells Fargo's financial model.
Wells Fargo has lowered its price target for Acelyrin from $15 to $13, while maintaining an Overweight rating on the shares.

Intellia Therapeutics Prioritizes Late-Stage Programs Following Promising Gene Editing Data

Intellia Therapeutics is focusing on advancing pivotal studies for ATTR and HAE, signaling a strategic prioritization of late-stage clinical programs.
Phase II trial results for NTLA-2002 in hereditary angioedema (HAE) showed a 77% reduction in attacks with the 50 mg dose over 16 weeks.

Intellia Therapeutics' NTLA-2002 Shows Promise in HAE but Faces Market Concerns

Intellia Therapeutics announced Phase 2 results for NTLA-2002, an investigational gene-editing therapy for hereditary angioedema (HAE), demonstrating a significant reduction in attack rates.
The trial, involving 27 participants, showed a 75% to 81% reduction in monthly HAE attack rates, with a higher dose group experiencing complete response in a majority of patients.

2Seventy Bio Halts Abecma Trial Amid Evolving Multiple Myeloma Treatment Landscape

2Seventy Bio has stopped enrolling patients in the Phase 3 KarMMa-9 study evaluating Abecma in newly diagnosed multiple myeloma patients with suboptimal responses to stem cell transplants.
The decision aims to save $80 million and help 2Seventy Bio achieve financial breakeven next year, following a $27 million operating loss in the second quarter.

Reference News

[1]
Intellia Therapeutics price target lowered to $70 from $80 ...
finance.yahoo.com · Nov 19, 2024

Wells Fargo reduced Intellia Therapeutics' price target to $70 from $80, maintaining an Overweight rating. Positive Phas...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy